Cargando…

Reducing laboratory costs through rational testing in suspected pre-eclampsia

The current electronic laboratory order set at Epsom and St Helier University Hospitals NHS Trust for suspected pre-eclampsia includes a full blood count, urea and electrolytes, liver function, gamma-glutamyltransferase and uric acid. Local and national guidelines do not recommend the use of gamma-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakes, Adam Daniel, Cox, Marsha, Drane, Simon, Johnson, Antoinette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915367/
https://www.ncbi.nlm.nih.gov/pubmed/35272997
http://dx.doi.org/10.1136/bmjoq-2021-001684
_version_ 1784668004957552640
author Jakes, Adam Daniel
Cox, Marsha
Drane, Simon
Johnson, Antoinette
author_facet Jakes, Adam Daniel
Cox, Marsha
Drane, Simon
Johnson, Antoinette
author_sort Jakes, Adam Daniel
collection PubMed
description The current electronic laboratory order set at Epsom and St Helier University Hospitals NHS Trust for suspected pre-eclampsia includes a full blood count, urea and electrolytes, liver function, gamma-glutamyltransferase and uric acid. Local and national guidelines do not recommend the use of gamma-glutamyltransferase or uric acid for the investigation or monitoring of pre-eclampsia, as they are poor predictors of maternal and neonatal outcomes. We aimed to remove the automatic inclusion of gamma-glutamyltransferase and uric acid from the electronic laboratory order set for suspected pre-eclampsia. Stakeholders were approached to gain an understanding of whether gamma-glutamyltransferase and uric acid were being used in the clinical assessment of suspected pre-eclampsia. Obstetric consultants and maternity staff confirmed that they do not use uric acid in their clinical assessment, despite the laboratory phoning with abnormal results. In addition, an isolated gamma-glutamyltransferase rise is of no particular significance and is not part of the National Institute for Health and Care Excellence (NICE) diagnostic criteria for pre-eclampsia. The baseline number of gamma-glutamyltransferase and uric acid requests from the maternity department was identified over 2 months. The hospital information technology service was then asked to remove gamma-glutamyltransferase and uric acid from the electronic laboratory order set. The number of gamma-glutamyltransferase and uric acid requests from the maternity department following the intervention was identified over 2 months. A significant reduction in both gamma-glutamyltransferase and uric acid requests were noted. In addition, the midwives within the maternity assessment unit noted a significant reduction in phone calls from the laboratory to escalate abnormal blood results. This has saved the trust money and reduced staff time answering phone calls regarding abnormal blood results. A repeat assessment at 8 months following the removal of gamma-glutamyltransferase and uric acid demonstrated sustainability of the project.
format Online
Article
Text
id pubmed-8915367
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89153672022-03-25 Reducing laboratory costs through rational testing in suspected pre-eclampsia Jakes, Adam Daniel Cox, Marsha Drane, Simon Johnson, Antoinette BMJ Open Qual Quality Improvement Report The current electronic laboratory order set at Epsom and St Helier University Hospitals NHS Trust for suspected pre-eclampsia includes a full blood count, urea and electrolytes, liver function, gamma-glutamyltransferase and uric acid. Local and national guidelines do not recommend the use of gamma-glutamyltransferase or uric acid for the investigation or monitoring of pre-eclampsia, as they are poor predictors of maternal and neonatal outcomes. We aimed to remove the automatic inclusion of gamma-glutamyltransferase and uric acid from the electronic laboratory order set for suspected pre-eclampsia. Stakeholders were approached to gain an understanding of whether gamma-glutamyltransferase and uric acid were being used in the clinical assessment of suspected pre-eclampsia. Obstetric consultants and maternity staff confirmed that they do not use uric acid in their clinical assessment, despite the laboratory phoning with abnormal results. In addition, an isolated gamma-glutamyltransferase rise is of no particular significance and is not part of the National Institute for Health and Care Excellence (NICE) diagnostic criteria for pre-eclampsia. The baseline number of gamma-glutamyltransferase and uric acid requests from the maternity department was identified over 2 months. The hospital information technology service was then asked to remove gamma-glutamyltransferase and uric acid from the electronic laboratory order set. The number of gamma-glutamyltransferase and uric acid requests from the maternity department following the intervention was identified over 2 months. A significant reduction in both gamma-glutamyltransferase and uric acid requests were noted. In addition, the midwives within the maternity assessment unit noted a significant reduction in phone calls from the laboratory to escalate abnormal blood results. This has saved the trust money and reduced staff time answering phone calls regarding abnormal blood results. A repeat assessment at 8 months following the removal of gamma-glutamyltransferase and uric acid demonstrated sustainability of the project. BMJ Publishing Group 2022-03-10 /pmc/articles/PMC8915367/ /pubmed/35272997 http://dx.doi.org/10.1136/bmjoq-2021-001684 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Quality Improvement Report
Jakes, Adam Daniel
Cox, Marsha
Drane, Simon
Johnson, Antoinette
Reducing laboratory costs through rational testing in suspected pre-eclampsia
title Reducing laboratory costs through rational testing in suspected pre-eclampsia
title_full Reducing laboratory costs through rational testing in suspected pre-eclampsia
title_fullStr Reducing laboratory costs through rational testing in suspected pre-eclampsia
title_full_unstemmed Reducing laboratory costs through rational testing in suspected pre-eclampsia
title_short Reducing laboratory costs through rational testing in suspected pre-eclampsia
title_sort reducing laboratory costs through rational testing in suspected pre-eclampsia
topic Quality Improvement Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915367/
https://www.ncbi.nlm.nih.gov/pubmed/35272997
http://dx.doi.org/10.1136/bmjoq-2021-001684
work_keys_str_mv AT jakesadamdaniel reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia
AT coxmarsha reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia
AT dranesimon reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia
AT johnsonantoinette reducinglaboratorycoststhroughrationaltestinginsuspectedpreeclampsia